ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...

ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...